
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.
Endocrinology saw significant advancements throughout the first 6 months of 2026, between major approvals from the US Food and Drug Administration (FDA) and key trial readouts regarding everything from obesity to type 1 (T1D) and type 2 diabetes (T2D).






